Promedior Announces Presentation of Data at ARVO Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models
—First-in-Class Pentraxin Therapeutic Represents a Promising New Mechanism for Treating Fibroproliferative Retinal Diseases—
MALVERN, PA, May 1, 2012 —Promedior, Inc.
, a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that data from preclinical studies of recombinant human Pentraxin-2 (rPTX-2) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 6-10, 2012, in Ft. Lauderdale, FL. The data to be presented highlight the efficacy of recombinant Pentraxin-2 in suppressing choroidal fibrosis and subretinal vascular leakage in independent models of age-related macular degeneration (AMD) and diabetic retinopathy, and confirm the potent effect of Pentraxin-2 on induction of regulatory macrophage activity in the retina.
Promedior is developing PRM-167 (rPTX-2 variant for intravitreal injection) for the treatment of fibroproliferative retinal diseases like AMD, diabetic retinopathy and proliferative vitreoretinopathy (PVR, retinal detachment). Pentraxin-2 is a natural human protein that regulates the cell populations, such as monocytes and macrophages, that control fibrosis, inflammation and pathologic neovascularization. In AMD and diabetic retinopathy, neovascularization and fibrosis are known to cause retinal damage which can result in visual impairment and progressive loss of vision.
The schedule and details of the presentation on the therapeutic potential of recombinant Pentraxin-2 for retinal diseases at ARVO are as follows:
: Recombinant Pentraxin-2 (rPTX-2) Shifts Macrophage Phenotype, Suppresses Subretinal NV, and Reduces Associated Vascular Leakage and Collagen Deposition
Retinal Disease Mechanisms and Treatment Modalities
Sunday, May 6, 2012, 3:15 PM - 5:00 PM
Program # / Board #:
1209-1226 / D1025-D1042
PRM-167 (rhPTX-2 variant for intravitreal injection) is a variant of a recombinant form of human Pentraxin-2 that is in development for the treatment of fibrovascular retinal diseases. Intravitreally administered rhPTX-2 has demonstrated robust preclinical efficacy in validated models of choroidal neovascularization, retinal neovascularization and proliferative vitreoretinopathy (PVR, retinal detachment). With a novel mechanism of action that is highly differentiated from other approaches to treat fibrovascular diseases, recombinant Pentraxin-2 therapeutics offer the potential to effectively reverse fibrotic and neovascular disease processes and promote normal healing.
is a clinical-stage biotechnology company developing a pipeline of novel Pentraxin-2 therapeutics for the treatment of fibrovascular diseases. Pentraxin-2 therapeutics treat fibrovascular diseases by naturally regulating monocyte-derived cells (macrophages and fibrocytes) that control the fibrotic process and drive pathologic neovascularization. Based on a unique mechanism of action
, Pentraxin-2 localizes to sites of tissue damage and stimulates monocytes to differentiate into regulatory macrophages rather than pro-fibrotic macrophages and fibrocytes, thereby reversing inflammatory, fibrotic and neovascular processes and promoting normal healing. By acting upstream of these pathologic processes using a natural regulatory pathway, Pentraxin-2 therapeutics provide a superior therapeutic approach and an inherently safer profile. For additional information about Promedior, please visit www.promedior.com
The Yates Network